NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
A Robust, Rapid and Scalable Cell Free Expression System for the Production and Engineering of Fab Antibodies
Garces, Eudean et. al., A robust, rapid and scalable cell free expression system for the production and engineering of Fab antibodies. Presented at the IBC 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Convention, San Diego, CA....
Sutro Biopharma Secures $36.5 Million in Series C Financing
South San Francisco, CA Nov. 17, 2010 - Sutro Biopharma today announced that the company has secured $36.5 million in Series C financing. This financing will support the company's ongoing development of novel biotherapeutics with superior pharmaceutical properties and...
Translation Fidelity Rate Determination in a Cell-Free Protein Synthesis System using LC-MS
Heibeck, Tyler H., et. al., Translation Fidelity Rate Determination in a Cell-Free Protein Synthesis System using LC-MS. 58th American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics,Salt Lake City, UT. Read More
Towards scalable cell-free synthesis of non-native amino acid containing proteins
Rozzelle, James E., et.al., Towards scalable cell-free synthesis of non-native amino acid containing proteins. Presented at American Chemical Society Spring Meeting, San Francisco, CA. Read More
Sutro Biopharma and Promising Protein Synthesis Technology
National Science Foundation (NSF) newsletter featuring Sutro Biopharma and Promising Protein Synthesis Technology. Read More
Sutro Biopharma Announces Additions to Board of Directors and Senior Management Team
South San Francisco, CA (August 20, 2009) Sutro Biopharma, Inc., the leader in open cell-free synthesis (OCFS) for the discovery and production of proteins, today announced several key appointments to the company’s management. Daniel H. Petree of P2 Partners, LLC has...
Sutro Biopharma Adds to Extensive IP Portfolio with Two Newly Issued Patents and Two Patent Grant Notices — Covers the Only Cell-Free Synthesis Platform Applicable to Protein Discovery Through Production —
South San Francisco, CA (June 9, 2009) Sutro Biopharma, Inc., the leader in open cell-free synthesis (OCFS) for the discovery and production of proteins, announced today that two additional patents, as well as two patent grant notices, have issued pertaining to...
Sutro Biopharma Hits Major Technical Milestone, Reaching 100 Liter Scale for the Company’s Open Cell-free Protein Synthesis Technology – Milestone Triggers $15 Million Series B Financing
South San Francisco, CA (March 30, 2009) Sutro Biopharma, Inc., a pioneer in open cell-free synthesis for the discovery and production of proteins, announced today the first ever achievement of therapeutic protein production at 100 L scale using a cell-free synthesis...
William J. Newell Named Chief Executive Officer of Sutro Biopharma – Former CEO Daniel S. Gold, Ph.D. Becomes President and Chief Operating Officer – Company Notes Name Change from Fundamental Applied Biology and Relocation to South San Francisco
South San Francisco, CA (January 12, 2009) Sutro Biopharma, Inc., formerly known as Fundamental Applied Biology, today announced the appointment of William J. Newell as Chief Executive Officer of the company. Daniel S. Gold, Ph.D., the company’s previous CEO becomes...